The inhibition of Treg activity by blocking CTLA4 (134) and PD-1 (132) represents an effective therapeutic target in some cases of melanoma, especially if both proteins are targeted simultaneously (135, 136), despite the risk of dose-dependent toxicity and autoimmune disorders. The gene discussed is PDCD1; the disease is autoimmune disease.